|
시장보고서
상품코드
1672817
만성 폐쇄성 폐질환(COPD) 치료 시장 : 약제 클래스별, 투여 경로별, 유통 채널별, 지역별Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Drug Class, By Route of Administration, By Distribution Channel, By Geography |
||||||
가격
※ 부가세 별도
한글목차
영문목차
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.
세계의 만성 폐쇄성 폐질환(COPD) 치료 시장은 2025년에는 203억 5,000만 달러로 추정되며, 2032년에는 304억 1,000만 달러에 달할 것으로 예측되며, 2025-2032년 연간 평균 성장률(CAGR)은 5.9%로 성장할 전망입니다.
| 리포트 범위 | 리포트 상세 | ||
|---|---|---|---|
| 기준연도 | 2024 | 2025년 시장 규모 | 203억 5,000만 달러 |
| 실적 데이터 | 2020-2024년 | 예측 기간 | 2025-2032년 |
| 예측 기간 : 2025-2032년 CAGR : | 5.90% | 2032년 가치 예측 | 304억 1,000만 달러 |
도표. 만성 폐쇄성 폐질환(COPD) 치료 시장 점유율(%), 2025년 지역별
만성폐쇄성폐질환(COPD)은 기류가 막히고 호흡 관련 문제를 일으키는 폐질환을 말합니다. COPD의 주요 원인으로는 담배 흡연, 먼지, 연기 등 작업장에서의 폐 자극 물질 노출, 대기 오염 등이 있으며, COPD의 주요 증상으로는 호흡곤란, 기침, 점액(가래) 분비, 천명음 등이 있습니다. 이 저하되어 호흡곤란이 발생합니다.
시장 역학:
세계 만성폐쇄성폐질환(COPD) 치료제 시장의 성장은 높은 흡연율, 전 세계 대기오염 수준 증가, 노인 인구 증가, 질병 및 치료 옵션에 대한 인식 증가 등의 요인에 기인합니다. 그러나 COPD 및 폐암과 같은 관련 합병증에 대한 완전한 치료법이 없습니다는 점이 시장 성장에 걸림돌이 될 수 있습니다. 제약회사들은 COPD에 대한 새로운 생물학적 제제의 연구개발에 투자하고 있으며, 이는 시장 성장에 유리한 기회를 제공할 수 있습니다. 기업들은 COPD의 증상과 악화를 효과적으로 치료하기 위해 에피네프린 자동주사기, 기관지 확장제, 흡입용 코르티코스테로이드, 병용요법 등을 개발하고 있습니다.
본 조사의 주요 특징
- 세계의 만성폐쇄성폐질환(COPD) 치료제 시장을 상세하게 분석했으며, 2024년을 기준 연도로 하여 예측 기간(2025-2032년) 시장 규모(미화억 달러)와 연평균 성장률(CAGR)에 대해 조사 분석하여 전해드립니다.
- 또한, 다양한 부문에 걸친 잠재적인 수익 성장 기회를 밝히고, 이 시장의 매력적인 투자 제안 매트릭스를 설명합니다.
- 또한 시장 성장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업의 경쟁 전략 등에 대한 중요한 고찰을 제공합니다.
- 세계 만성폐쇄성폐질환(COPD) 치료제 시장의 주요 기업 프로파일을 기업 개요, 제품 포트폴리오, 주요 특징, 주요 성과, 전략 등을 기준으로 정리하여 수록하였습니다.
- 주요 기업에는 AstraZeneca, Orion Corporation, Mylan N.V., Teva Pharmaceutical Industries Ltd., GSK plc, Novartis AG, Sunovion Pharmaceuticals, Inc, CHIESI Farmaceutici SpA, Alembic Pharmaceuticals Ltd, Verona Pharmaceuticals, Theravance Biopharma, F. Hoffmann-La Roche Ltd, Sanofi, Boehringer Ingelheim International GmbH, Merck &Co., Inc, Grifols, S.A., Almirall, S.A., Genentech, Inc. 등이 있습니다.
- 이 보고서의 통찰력을 통해 마케팅 담당자와 기업 경영진은 향후 제품 출시, 유형화, 시장 확대, 마케팅 전략에 대한 정보에 입각한 의사결정을 내릴 수 있습니다.
- 세계 만성폐쇄성폐질환(COPD) 치료제 시장은 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 시장 진출기업, 재무 분석가 등 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 세계 만성폐쇄성폐질환(COPD) 치료제 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정을 용이하게 할 수 있습니다.
제1장 조사의 목적과 전제조건
- 조사 목적
- 전제조건
- 약어
제2장 시장 전망
- 리포트 설명
- 시장의 정의와 범위
- 개요
- Coherent Opportunity Map(COM)
제3장 시장 역학, 규제, 동향 분석
- 시장 역학
- 촉진요인
- 억제요인
- 기회
- 영향 분석
- 역학
- 시장 동향
- 주요 발전
- 규제 시나리오
- 제조업체 매출
- 인수와 제휴 시나리오
- 제품 발매/승인
- 자금조달과 투자
- PEST 분석
- Porter의 산업 분석
제4장 세계의 만성 폐쇄성 폐질환(COPD) 치료 시장 - 코로나바이러스(COVID-19) 팬데믹의 영향
- 전체적인 영향
- 정부 구상
- 시장에 대한 COVID-19의 영향
제5장 세계의 만성 폐쇄성 폐질환(COPD) 치료 시장, 약제 클래스별, 2020-2032년(10억 달러)
- 기관지 확장약
- 포스포디에스테라제 4 저해제
- 코르티코스테로이드
- 기타
제6장 세계의 만성 폐쇄성 폐질환(COPD) 치료 시장, 투여 경로별, 2020-2032년, (10억 달러)
- 경구
- 흡입
제7장 세계의 만성 폐쇄성 폐질환(COPD) 치료 시장, 유통 채널별, 2020-2032년, (10억 달러)
- 병원 약국
- 소매 약국
- 온라인 약국
제8장 세계의 만성 폐쇄성 폐질환(COPD) 치료 시장, 지역별, 2020-2032년, (10억 달러)
- 북미
- 라틴아메리카
- 유럽
- 아시아태평양
- 중동
- 아프리카
제9장 경쟁 구도
- 기업 개요
- AstraZeneca
- Orion Corporation
- Mylan NV
- Teva Pharmaceutical Industries Ltd.
- GSK plc
- Novartis AG
- Sunovion Pharmaceuticals, Inc.
- CHIESI Farmaceutici SpA
- Alembic Pharmaceuticals Ltd
- Verona Pharmaceuticals
- Theravance Biopharma
- F. Hoffmann-La Roche Ltd
- Sanofi
- Boehringer Ingelheim International GmbH
- Merck &Co., Inc
- Grifols, SA
- Almirall, SA
- Genentech, Inc
제10장 애널리스트의 권장사항
제11장 참고 문헌과 조사 방법
- 참고 문헌
- 조사 방법
Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market is estimated to be valued at USD 20.35 Bn in 2025 and is expected to reach USD 30.41 Bn by 2032, growing at a compound annual growth rate (CAGR) of 5.9% from 2025 to 2032.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2024 | Market Size in 2025: | USD 20.35 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2025 To 2032 |
| Forecast Period 2025 to 2032 CAGR: | 5.90% | 2032 Value Projection: | USD 30.41 Bn |
Figure. Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Region 2025
Chronic obstructive pulmonary disease (COPD) refers to a group of lung diseases that cause airflow blockage and breathing-related problems. It includes emphysema and chronic bronchitis. Key causes of COPD include tobacco smoking, exposure to lung irritants in the workplace like dusts and fumes, and air pollution. The main symptoms of COPD include shortness of breath, cough, mucus (sputum) production, and wheezing. As COPD progresses, lung function deteriorates over time, resulting in breathlessness.
Market Dynamics:
Global chronic obstructive pulmonary disease (COPD) treatment market growth is driven by factors such as high prevalence of tobacco smoking, increasing air pollution levels worldwide, rising geriatric population, and a growing awareness about the disease and available therapeutic options. However, lack of complete cure for COPD and related complications like lung cancer can hamper the market growth. Pharmaceutical companies investing in research and development of novel biologic drugs for COPD can offer lucrative opportunities for the market growth. Companies are developing epinephrine auto-injectors, bronchodilators, inhaled corticosteroids and combination therapies to effectively treat COPD symptoms and exacerbations.
Key Features of the Study:
- This report provides an in-depth analysis of the global chronic obstructive pulmonary disease (COPD) treatment market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
- It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global chronic obstructive pulmonary disease (COPD) treatment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this include AstraZeneca, Orion Corporation, Mylan N.V., Teva Pharmaceutical Industries Ltd., GSK plc, Novartis AG, Sunovion Pharmaceuticals, Inc., CHIESI Farmaceutici SpA, Alembic Pharmaceuticals Ltd, Verona Pharmaceuticals, Theravance Biopharma, F. Hoffmann-La Roche Ltd, Sanofi, Boehringer Ingelheim International GmbH, Merck & Co., Inc, Grifols, S.A., Almirall, S.A, Genentech, Inc
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- Global chronic obstructive pulmonary disease (COPD) treatment market caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global chronic obstructive pulmonary disease (COPD) treatment market
Detailed Segmentation-
- By Drug Class:
- Bronchodilators
- Beta 2-Agonists
- Anticholinergics
- Theophyllines
- Phosphodiesterase Type 4 Inhibitors
- Corticosteroids
- Others
- By Route of Administration:
- Oral
- Inhalation
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
- Company Profiles:
- AstraZeneca
- Orion Corporation
- Mylan N.V.
- Teva Pharmaceutical Industries Ltd.
- GSK plc
- Novartis AG
- Sunovion Pharmaceuticals, Inc.
- CHIESI Farmaceutici SpA
- Alembic Pharmaceuticals Ltd
- Verona Pharmaceuticals
- Theravance Biopharma
- Hoffmann-La Roche Ltd
- Sanofi
- Boehringer Ingelheim International GmbH
- Merck & Co., Inc
- Grifols, S.A.
- Almirall, S.A
- Genentech, Inc
Table of Contents (TOC)
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Drug Class
- Market Snapshot, By Route of Administration
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Opportunities
- Impact Analysis
- Epidemiology
- Market Trends
- Key Developments
- Regulatory Scenario
- Manufacturer Revenue
- Acquisitions and Partnerships Scenario
- Product Launches/Approvals
- Funding and Investments
- PEST Analysis
- Porter's Analysis
4. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market - Impact of Coronavirus (COVID-19) Pandemic
- Overall Impact
- Government Initiatives
- COVID-19 Impact on the Market
5. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Drug Class, 2020 - 2032, (USD Bn)
- Overview
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Bronchodilators
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Beta 2-Agonists
- Anticholinergics
- Theophyllines
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Phosphodiesterase Type 4 Inhibitors
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Corticosteroids
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
6. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Route of Administration, 2020 - 2032, (USD Bn)
- Overview
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Oral
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Inhalation
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
7. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Distribution Channel, 2020 - 2032, (USD Bn)
- Overview
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Hospital Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Retail Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Online Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
8. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Region, 2020 - 2032, (USD Bn)
- Introduction
- Market Share Analysis, By Region, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, For Region, 2021-2032
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020 - 2032, (USD Bn)
- North Africa
- Central Africa
- South Africa
9. Competitive Landscape
- Company Profiles
- AstraZeneca*
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Orion Corporation
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Mylan N.V.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Teva Pharmaceutical Industries Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- GSK plc
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Novartis AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Sunovion Pharmaceuticals, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- CHIESI Farmaceutici SpA
- Alembic Pharmaceuticals Ltd
- Verona Pharmaceuticals
- Theravance Biopharma
- F. Hoffmann-La Roche Ltd
- Sanofi
- Boehringer Ingelheim International GmbH
- Merck & Co., Inc
- Grifols, S.A.
- Almirall, S.A
- Genentech, Inc
- AstraZeneca*
10. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
11. References and Research Methodology
- References
- Research Methodology
- About us and Sales Contact
